[go: up one dir, main page]

WO2014162008A3 - Nouvelle signature de biomarqueur et ses utilisations - Google Patents

Nouvelle signature de biomarqueur et ses utilisations Download PDF

Info

Publication number
WO2014162008A3
WO2014162008A3 PCT/EP2014/056879 EP2014056879W WO2014162008A3 WO 2014162008 A3 WO2014162008 A3 WO 2014162008A3 EP 2014056879 W EP2014056879 W EP 2014056879W WO 2014162008 A3 WO2014162008 A3 WO 2014162008A3
Authority
WO
WIPO (PCT)
Prior art keywords
lymphoma
hodkin
drug response
individual
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2014/056879
Other languages
English (en)
Other versions
WO2014162008A2 (fr
Inventor
Shahid Mian
Ahmed MOHAMEDEN
Ibraheim ASHANKYTY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HA'IL, University of
Original Assignee
HA'IL, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HA'IL, University of filed Critical HA'IL, University of
Publication of WO2014162008A2 publication Critical patent/WO2014162008A2/fr
Publication of WO2014162008A3 publication Critical patent/WO2014162008A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé in vitro de détermination de la sensibilité d'un individu atteint de lymphome de Hodgkin à un traitement par médicament chimiothérapeutique, le procédé comprenant les étapes de fourniture d'une protéine ou d'un échantillon d'ARNm provenant d'un ganglion lymphatique de l'individu à tester, puis de détermination de la présence et/ou de la quantité dans les échantillons d'au moins deux protéines choisies dans le groupe identifié dans le Tableau A, et/ou d'ARNm codant pour ces dernières, la présence et/ou la quantité dans l'échantillon des protéines choisies dans le groupe défini dans le Tableau A, ou de l'ARNm codant pour ces dernières, indiquent la sensibilité de l'individu atteint de lymphome de Hodgkin au traitement par médicament chimiothérapeutique. L'invention concerne en outre des gammes et des trousses à utiliser dans ce dernier.
PCT/EP2014/056879 2013-04-05 2014-04-04 Nouvelle signature de biomarqueur et ses utilisations Ceased WO2014162008A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1306147.8A GB201306147D0 (en) 2013-04-05 2013-04-05 Novel biomarker signature and uses thereof
GB1306147.8 2013-04-05

Publications (2)

Publication Number Publication Date
WO2014162008A2 WO2014162008A2 (fr) 2014-10-09
WO2014162008A3 true WO2014162008A3 (fr) 2015-01-08

Family

ID=48483371

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/056879 Ceased WO2014162008A2 (fr) 2013-04-05 2014-04-04 Nouvelle signature de biomarqueur et ses utilisations

Country Status (2)

Country Link
GB (1) GB201306147D0 (fr)
WO (1) WO2014162008A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10961589B2 (en) 2015-03-05 2021-03-30 Case Western Reserve University HER2-regulated RNA as a diagnostic and therapeutic targets in HER2+ breast cancer
CN107217105B (zh) * 2017-07-27 2020-10-20 江苏省原子医学研究所 一种癌症联合诊断标记物及其用途
EP3578981B1 (fr) * 2018-06-06 2021-10-27 TUDAG TU Dresden Aktiengesellschaft Traitement anticancéreux de sujets présélectionnée et procédés de criblage permettant d'identifier des sujets prédisposés
RU2688313C1 (ru) * 2018-10-02 2019-05-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ прогнозирования инфертильности после риск-адаптированного лечения лимфомы ходжкина у детей и подростков
CN111228289A (zh) * 2018-11-28 2020-06-05 中国科学院大连化学物理研究所 Plin2抑制剂的应用和治疗肿瘤药物混合物
CN111235269A (zh) * 2018-11-28 2020-06-05 中国科学院大连化学物理研究所 Plin2及定量检测plin2的试剂的应用和试剂盒
AU2020309312A1 (en) * 2019-07-05 2022-01-27 Intellexon Gmbh Methods for diagnosing the effectiveness of anti-tumor treatment
EP3909600A1 (fr) 2020-05-12 2021-11-17 International Centre For Genetic Engineering And Biotechnology - ICGEB Protéine emid2 en tant que traitement anticancéreux
EP4443162A1 (fr) * 2023-04-03 2024-10-09 Fundación Para La Investigación Biomédica Del Hospital Clínico San Carlos Signature génétique pour prédire la réponse aux immunotherapies chez un patient
CN119932197B (zh) * 2025-04-09 2025-06-13 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 磷酸二酯酶6d作为前列腺癌用药指导标志物的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006135886A2 (fr) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions et methodes pour le traitement et le diagnostic du cancer
WO2010118782A1 (fr) * 2009-04-17 2010-10-21 Universite Libre De Bruxelles Procédés et outils pour prédire l'efficacité d'anthracyclines dans le traitement du cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006135886A2 (fr) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions et methodes pour le traitement et le diagnostic du cancer
WO2010118782A1 (fr) * 2009-04-17 2010-10-21 Universite Libre De Bruxelles Procédés et outils pour prédire l'efficacité d'anthracyclines dans le traitement du cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FATIH M. UCKUN ET AL: "Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network", BRITISH JOURNAL OF HAEMATOLOGY, vol. 153, no. 6, 25 April 2011 (2011-04-25), pages 741 - 752, XP055131235, ISSN: 0007-1048, DOI: 10.1111/j.1365-2141.2011.08671.x *
STAEGE M S ET AL: "Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC, US, vol. 36, no. 7, 1 July 2008 (2008-07-01), pages 886 - 896, XP022736036, ISSN: 0301-472X, [retrieved on 20080408], DOI: 10.1016/J.EXPHEM.2008.02.014 *

Also Published As

Publication number Publication date
WO2014162008A2 (fr) 2014-10-09
GB201306147D0 (en) 2013-05-22

Similar Documents

Publication Publication Date Title
WO2014162008A3 (fr) Nouvelle signature de biomarqueur et ses utilisations
WO2014186761A3 (fr) Procédés pour déterminer la réactivité à un agent anti-cd47
WO2015067969A3 (fr) Procédé, réseau et leur utilisation
MX2020004617A (es) Prediccion de riesgo de evento cardiovascular y usos del mismo.
SA521421882B1 (ar) نظم، وطرق وجهاز لتمديد مجموعة من الخلايا
MX363201B (es) Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico.
MX2018013621A (es) Metodo, matriz y uso de estos.
EA030186B9 (ru) Способ проведения количественных анализов
WO2011109372A8 (fr) Détection ultrasensible de molécules à l'aide de procédés de type double détection
IN2014KN02647A (fr)
NZ621733A (en) Lung cancer biomarkers and uses thereof
MX392706B (es) Ensayo a base de células para detectar homodímeros anti-cd3.
AR089825A1 (es) Metodo para determinar la ubicacion, tamaño y condiciones in situ en un yacimiento de hidrocarburos con ecologia, geoquimica y grupos de biomarcadores
MX2019008911A (es) Metodos, matrices y usos de estos.
EP3165923A4 (fr) Marqueur, méthode de dosage immunologique, réactif de dosage immunologique, méthode de dosage d'analyte, kit de dosage d'analyte, et bandelette réactive pour chromatographie à écoulement latéral
AR092350A1 (es) Sistema y metodo automaticos para la produccion, aplicacion y evaluacion de composiciones de recubrimiento
EP4328587A3 (fr) Utilisation d'un kit ou d'un dispositif et méthode de détection de la démence
WO2012032345A3 (fr) Signatures de biomarqueurs et leurs applications
WO2015091575A3 (fr) Niveaux différents de marqueurs emt dans des échantillons de cellules sanguines pour le diagnostic du cancer, en particulier du cancer colorectal (crc) et du cancer pancréatique (pc)
EP3557259A3 (fr) Procédés et réseaux destinés à être utilisés avec ceux-ci
GB201206323D0 (en) Methods and arrays for use in the same
EP2937421A3 (fr) Biomarqueur permettant de prédire l'effet d'un anticorps dirigé contre c-Met
MX2018015140A (es) Firmas de biomarcadores de lupus eritematoso sistemico y sus usos.
EA201691168A1 (ru) Способы исследования бета-глюкана
HK1212185A1 (en) System and method for determining hematocrit insensitive glucose concentration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14721223

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14721223

Country of ref document: EP

Kind code of ref document: A2